middle.news
Cynata Therapeutics Awaits Pivotal Phase 2 and 3 Trial Results Amid Capital Raise
10:42am on Thursday 30th of April, 2026 AEST
•
Biotechnology
Read Story
Cynata Therapeutics Awaits Pivotal Phase 2 and 3 Trial Results Amid Capital Raise
10:42am on Thursday 30th of April, 2026 AEST
Key Points
Phase 2 aGvHD trial results expected June 2026
Phase 3 osteoarthritis trial results due May 2026
Cash balance of $1.6 million with trading halt for capital raise
Strengthened intellectual property with new US patent grant
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE